Statements of Operations (Mymd Pharmaceuticals Inc.) - USD ($) |
12 Months Ended | |
|---|---|---|
Dec. 31, 2020 |
Dec. 31, 2019 |
|
| Revenues | ||
| Operating Costs: | ||
| General and administrative expenses (including $855,000, $3,577,550 of share-based compensation for 2020 and 2019, respectively) | 4,299,062 | 3,372,103 |
| Research and development expenses | 7,963,678 | |
| Net Loss | (17,580,609) | (3,888,249) |
| Mymd Pharmaceuticals Inc. [Member] | ||
| Revenues | ||
| Operating Costs: | ||
| General and administrative expenses (including $855,000, $3,577,550 of share-based compensation for 2020 and 2019, respectively) | 3,304,673 | 5,764,986 |
| Research and development expenses | 2,241,431 | 3,627,739 |
| Option modification expense | 2,009,145 | |
| Total Operating Costs | 7,555,249 | 9,392,725 |
| Interest Expense | (1,375,216) | (246,191) |
| Net Loss | $ (8,930,465) | $ (9,638,916) |
| X | ||||||||||
- Definition Option modification expense. No definition available.
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of the cost of borrowed funds accounted for as interest expense. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|